The Effect of Licorice Root Extract on the Treatment of Patients with Covid-19

INTERVENTION: Intervention 1: Consumption of capsules containing licorice extract in the intervention group.Alcoholic extract of licorice root will be purchased from Shirin Daroo Company and will be received in sterile packages. Prior to purchase, the manufacturer will receive a Certificate of Sale and Good Manufacturing Practice. The received sample will be sent to Zarband Pharmaceutical Company before the final order for glycyrrhizin content analysis and microbial test and the result of the analysis will be received. Alcoholic extract of licorice will be obtained from Shirin Daroo company along with COA product analysis sheet.Then, the sample will be sent to Zardband Pharmaceutical Company for confirmation of the mentioned parameters and final approval according to the standards mentioned in international pharmacopoeias. The extract will be added and mixed thoroughly. The powder obtained in the pharmaceutical factory (Osweh, Iran) will be packaged in an orange gelatin capsule (400 mg) and in a brown opaque can. Capsules containing licorice extract will be taken for one month in the amount of one capsule the day after lunch with a glass of water. Intervention 2: Control group: Placebo in capsules with the same color and size as the drug in cans similar to capsules containing licorice. Microcrystalline cellulose composition under the brand name AVICEL (particle diameter: less than 50 micrometers) as a placebo from the pharmaceutical company (Elixir , Iran) will be purchased. Placebo capsules will be taken for one month in the amount of one capsule per day after lunch with a glass of water. CONDITION: People with COVID 19 whose disease has been confirmed by Real Time PCR. ; U07.1 PRIMARY OUTCOME: Alpha tumor necrosis factor(TNF‐a). Timepoint: Major measurements of variables are performed on the first day before the intervention and on the 10th day after the intervention. Method of measurement: Using the kit. Interleukin 6( IL‐6). Timepoint: Major measurements of variables are performed on the first day before the intervention and on the 10th day after the intervention. Method of measurement: Using the kit. Interleukin One Beta( IL‐1ß). Timepoint: Major measurements of variables are performed on the first day before the intervention and on the 10th day after the intervention. Method of measurement: Using the kit. INCLUSION CRITERIA: Includes people with laboratory confirmation of Quid 19 virus regardless of clinical signs and close association Age over 15 years SECONDARY OUTCOME: C Reactive Protein (CRP). Timepoint: Sampling is done on the first day before the intervention and on the 10th day after the intervention for the main and routine variables of the study. Method of measurement: Through a clinical laboratory. D ‐Dimmer. Timepoint: Sampling is done on the first day before the intervention and on the 10th day after the intervention for the main and routine variables of the study. Method of measurement: Through a clinical laboratory. Ferritin. Timepoint: Sampling is done on the first day before the intervention and on the 10th day after the intervention for the main and routine variables of the study. Method of measurement: Through a clinical laboratory. Fibrinogen. Timepoint: Sampling is done on the first day before the intervention and on the 10th day after the intervention for the main and routine variables of the study. Method of measurement: Through a clinical laboratory. The international normalized ratio (INR). Timepoint: Sampling is done on the first day before the intervention and on the 10th day after the intervention for the main and routine variables of the study. Method of measurement: Through a clinical laboratory.